C3 and paroxysmal nocturnal hemoglobinuria: Among them, Pegcetacoplan (Apellis, Waltham, MA, USA), a pegylated anti-C3 cyclic peptide, has already been approved by regulatory agencies for the treatment of PNH in patients who do not respond adequately to Eculizumab.